Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Gastrointestinal 6Breast 5Thoracic 3Tumor-Agnostic 2Other neoplasm 2Lymphoid 2Head & Neck 2Other hematologic neoplasm 1Other 1Myeloid 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Non-melanoma Skin Cancer 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vitamin E × Dermatologic × Clear all
NCT00392561 2023-04-26

BEST

University of Chicago

Phase NA Completed
7,000 enrolled
Dermatologic

Non-melanoma Skin Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡